RxDoctor Payments Data

Jon Rosser, MD

Colon & Rectal Surgery · Birmingham, ALNPI 1528052818

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (53.0%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 88.1% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $6,805 and has fallen 98.5% since, to $105 in 2025.

$7,554in general payments, 2019–2025

Across 58 payments — averaging $130.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$7K
  • Johnson & Johnson$198
  • Takeda Pharmaceuticals U.S.A., Inc.$190
  • Axonics, Inc.$78
  • Medtronic$73
  • Myriad Genetic Laboratories, Inc.$32
  • plus $330 from 18 others

What the payments were for

  • Travel & lodging$2,45933%
  • Food & beverage$1,09514%
  • Education$4,00053%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few colon & rectal surgery providers in Alabamato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$90,433
Medicare patients
247
Services billed
495

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mesalamine44$16,600
Mesalamine ErMesalamine34$2,964
Budesonide DrBudesonide12$2,093
Colestipol Hcl45$1,812
Sulfasalazine28$745
Sulfasalazine DrSulfasalazine12$673
Dicyclomine Hcl23$283
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen32$131
Metronidazole27$110
Neomycin Sulfate14$76

Paid to pharmacies, not to this prescriber.

Other colon & rectal surgery in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →